177 related articles for article (PubMed ID: 19120715)
1. Metabolic and antihypertensive effects of combined angiotensin receptor blocker and diuretic therapy in prediabetic hypertensive patients with the cardiometabolic syndrome.
Zappe DH; Sowers JR; Hsueh WA; Haffner SM; Deedwania PC; Fonseca VA; Keeling L; Sica DA
J Clin Hypertens (Greenwich); 2008 Dec; 10(12):894-903. PubMed ID: 19120715
[TBL] [Abstract][Full Text] [Related]
2. Randomized study to compare valsartan +/- HCTZ versus amlodipine +/- HCTZ strategies to maximize blood pressure control.
Zappe D; Papst CC; Ferber P;
Vasc Health Risk Manag; 2009; 5():883-92. PubMed ID: 19898644
[TBL] [Abstract][Full Text] [Related]
3. Effects of the angiotensin II receptor blockers telmisartan vs valsartan in combination with hydrochlorothiazide 25 mg once daily for the treatment of hypertension.
White WB; Punzi HA; Murwin D; Koval SE; Davidai G; Neutel JM
J Clin Hypertens (Greenwich); 2006 Sep; 8(9):626-33. PubMed ID: 16957424
[TBL] [Abstract][Full Text] [Related]
4. Triple combination therapy with amlodipine, valsartan, and hydrochlorothiazide vs dual combination therapy with amlodipine and hydrochlorothiazide for stage 2 hypertensive patients.
Destro M; Crikelair N; Yen J; Glazer R
Vasc Health Risk Manag; 2010 Sep; 6():821-7. PubMed ID: 20859551
[TBL] [Abstract][Full Text] [Related]
5. Improving blood pressure control: increase the dose of diuretic or switch to a fixed-dose angiotensin receptor blocker/diuretic? the valsartan hydrochlorothiazide diuretic for initial control and titration to achieve optimal therapeutic effect (Val-DICTATE) trial.
White WB; Calhoun DA; Samuel R; Taylor AA; Zappe DH; Purkayastha D
J Clin Hypertens (Greenwich); 2008 Jun; 10(6):450-8. PubMed ID: 18550935
[TBL] [Abstract][Full Text] [Related]
6. Combination therapy versus monotherapy as initial treatment for stage 2 hypertension: a prespecified subgroup analysis of a community-based, randomized, open-label trial.
Everett BM; Glynn RJ; Danielson E; Ridker PM;
Clin Ther; 2008 Apr; 30(4):661-72. PubMed ID: 18498915
[TBL] [Abstract][Full Text] [Related]
7. Antihypertensive and metabolic effects of Angiotensin receptor blocker/diuretic combination therapy in obese, hypertensive African American and white patients.
Ofili EO; Zappe DH; Purkayastha D; Samuel R; Sowers JR
Am J Ther; 2013 Jan; 20(1):2-12. PubMed ID: 22248871
[TBL] [Abstract][Full Text] [Related]
8. Achieving blood pressure goal: initial therapy with valsartan/hydrochlorothiazide combination compared with monotherapy.
Weinberger MH; Glazer RD; Crikelair NA; Chiang YT
J Hum Hypertens; 2010 Dec; 24(12):823-30. PubMed ID: 20182456
[TBL] [Abstract][Full Text] [Related]
9. Combination therapy with valsartan/hydrochlorothiazide at doses up to 320/25 mg improves blood pressure levels in patients with hypertension inadequately controlled by valsartan 320 mg monotherapy.
Tuomilehto J; Tykarski A; Baumgart P; Reimund B; Le Breton S; Ferber P
Blood Press Suppl; 2008 Jun; 1():15-23. PubMed ID: 18705531
[TBL] [Abstract][Full Text] [Related]
10. Valsartan and hydrochlorothiazide in patients with essential hypertension. A multiple dose, double-blind, placebo controlled trial comparing combination therapy with monotherapy.
Benz JR; Black HR; Graff A; Reed A; Fitzsimmons S; Shi Y
J Hum Hypertens; 1998 Dec; 12(12):861-6. PubMed ID: 9883710
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study.
Ruilope LM; Malacco E; Khder Y; Kandra A; Bönner G; Heintz D
Clin Ther; 2005 May; 27(5):578-87. PubMed ID: 15978306
[TBL] [Abstract][Full Text] [Related]
12. Ambulatory blood pressure response to triple therapy with an angiotensin-receptor blocker (ARB), calcium-channel blocker (CCB), and HCTZ versus dual therapy with an ARB and HCTZ.
Duprez D; Ferdinand K; Purkayastha D; Samuel R; Wright R
Vasc Health Risk Manag; 2011; 7():701-8. PubMed ID: 22174580
[TBL] [Abstract][Full Text] [Related]
13. A home blood pressure monitoring study comparing the antihypertensive efficacy of two angiotensin II receptor antagonist fixed combinations.
Bobrie G; Delonca J; Moulin C; Giacomino A; Postel-Vinay N; Asmar R;
Am J Hypertens; 2005 Nov; 18(11):1482-8. PubMed ID: 16280286
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and tolerability of combination therapy with valsartan/hydrochlorothiazide in the initial treatment of severe hypertension.
Calhoun DA; Glazer RD; Pettyjohn FS; Coenen PD; Zhao Y; Grosso A
Curr Med Res Opin; 2008 Aug; 24(8):2303-11. PubMed ID: 18593517
[TBL] [Abstract][Full Text] [Related]
15. A 52-week prospective, cohort study of the effects of losartan with or without hydrochlorothiazide (HCTZ) in hypertensive patients with metabolic syndrome.
Racine N; Hamet P; Sampalis JS; Longo N; Bastien N
J Hum Hypertens; 2010 Nov; 24(11):739-48. PubMed ID: 20147971
[TBL] [Abstract][Full Text] [Related]
16. Combination therapy with various combinations of aliskiren, valsartan, and hydrochlorothiazide in hypertensive patients not adequately responsive to hydrochlorothiazide alone.
Geiger H; Barranco E; Gorostidi M; Taylor A; Zhang X; Xiang Z; Zhang J
J Clin Hypertens (Greenwich); 2009 Jun; 11(6):324-32. PubMed ID: 19527323
[TBL] [Abstract][Full Text] [Related]
17. Angiotensin receptor blocker/diuretic combination preserves insulin responses in obese hypertensives.
Sowers JR; Raij L; Jialal I; Egan BM; Ofili EO; Samuel R; Zappe DH; Purkayastha D; Deedwania PC
J Hypertens; 2010 Aug; 28(8):1761-9. PubMed ID: 20498618
[TBL] [Abstract][Full Text] [Related]
18. Antihypertensive efficacy of Irbesartan/HCTZ in men and women with the metabolic syndrome and type 2 diabetes.
Sowers JR; Neutel JM; Saunders E; Bakris GL; Cushman WC; Ferdinand KC; Ofili EO; Weber MA;
J Clin Hypertens (Greenwich); 2006 Jul; 8(7):470-80. PubMed ID: 16849900
[TBL] [Abstract][Full Text] [Related]
19. Office and ambulatory blood pressure-lowering effects of combination valsartan/hydrochlorothiazide vs. hydrochlorothiazide-based therapy in obese, hypertensive patients.
Raij L; Egan BM; Zappe DH; Purkayastha D; Samuel R; Sowers JR
J Clin Hypertens (Greenwich); 2011 Oct; 13(10):731-8. PubMed ID: 21974760
[TBL] [Abstract][Full Text] [Related]
20. The role of baseline blood pressure in guiding treatment choice: a secondary analysis of the use of valsartan/hydrochlorothiazide as initial therapy in hypertensive adults in a randomized, double-blind, placebo-controlled trial.
Pool JL; Glazer R; Crikelair N; Levy D
Clin Drug Investig; 2009; 29(12):791-802. PubMed ID: 19888785
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
